Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

LA JOLLA, Calif., May 14, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its microRNA therapeutic pipeline under the company's 'Road to the Clinic' strategy and reported financial results for the quarter ended March 31, 2013. 

Regulus Continues to Execute on 'Road to the Clinic' Strategy:
Nominated RG-101 as First microRNA Candidate for Clinical Development

  • Regulus announced today that it has nominated its first microRNA candidate for clinical development, RG-101, a GalNAc-conjugated microRNA antagonist or anti-miR, which targets microRNA-122 (miR-122) for the treatment of patients with chronic hepatitis C virus (HCV) infection. Regulus is performing additional pre-clinical studies and finalizing development plans for RG-101 in HCV and expects to submit an application with regulatory authorities in early 2014. 
  • Regulus plans to develop RG-101 independently of its strategic alliance with GlaxoSmithKline (GSK).  The broad strategic alliance between Regulus and GSK remains intact and GSK retains its interest in the miR-122 program in HCV, as miR-122 will remain a Collaboration Target under the alliance.
    As such, the companies are in the process of amending the Product Development and Commercialization Agreement to clarify that RG-101 is fully owned by Regulus. 
  • "The nomination of RG-101 as our first microRNA candidate for clinical development marks a tremendous milestone for Regulus and represents significant achievement of our initial goals under our 'Road to the Clinic' strategy," said Kleanthis G. Xanthopoulos , Ph.D., President and CEO of Regulus. "We
    '/>"/>

    SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    3. Regulus to Present at Future Leaders in the Biotech Industry Conference
    4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
    5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
    6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
    7. Regulus to Present at Two Upcoming Investor Conferences
    8. Regulus Appoints Mark G. Foletta to its Board of Directors
    9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
    10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
    11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... -- CHINA AID, the 10 ... Medicine and Healthcare, second to none in ... at Shanghai New International Expo Center on 22-24 April. ... on Encouraging Private Capital to Participate in the Development ... by the Ministry of Civil Affairs of the ...
    (Date:3/27/2015)... , March 27, 2015  Valeant Pharmaceuticals International, Inc. ... closing of its previously announced registered offering of common ... (the "Offering"). Pursuant to the Offering, the Company issued ... share, for aggregate gross proceeds of approximately $1.45 billion. ... U.S. Securities and Exchange Commission a final prospectus supplement ...
    (Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
    Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
    ... 2011 The National Community Pharmacists Association ... Consumer Choice Act of 2011 , which would ... of their choice, eliminate needless pharmaceutical spending and ... audits. (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ...
    ... May 24, 2011 CVS Caremark today outlined ... program designed to encourage patients to take their ... program show increases in consumers signing up for ... medications for brand medicines to lower costs. ...
    Cached Medicine Technology:Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 2Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 3CVS Caremark Research Tailors Consumer Communications to Encourage Better Medication Behavior 2CVS Caremark Research Tailors Consumer Communications to Encourage Better Medication Behavior 3
    (Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
    (Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... may not be necessary, according to research presented today ... AOSSM ) Specialty Day. , “Our study compared results ... 25 who underwent an additional glenohumeral joint capsule release ... commented George Murrell MD, PhD, lead author from St. ...
    (Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
    (Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
    (Date:3/27/2015)... Alberta (PRWEB) March 27, 2015 In her ... then, prevented her from working, Monica K. arrived at ... the mending department quiet, defensive and scared. The owners and ... & Support Services (EPSS) to offer jobs to challenged ... take patience and a willingness to begin with the end ...
    Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
    ... Aug. 12 Following an overwhelmingly,successful launch ... Wellcorps,International, the leading innovator of multi-benefit health ... WellCapAM(TM),Activation Complex is now available to the ... combination of 24 nutrients,antioxidants, and adaptogens that ...
    ... VIEW, Calif., Aug. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ... 30, 2008., The net loss for the second quarter ... during the same period in 2007. The net,loss for the ... $15.3,million for the first six months of 2007. As of ...
    ... Ind., Aug. 12 Hillenbrand, Inc.,(NYSE: HI ... consistent,with $165.6 million reported in the third quarter ... third-quarter earnings per share, operating,profit and cash flow ... for the quarter remained essentially flat, even as ...
    ... offer free skin screenings in first-ever, outreach for Pilot Pen Tennis fans ... ... women, NEW HAVEN, Conn., Aug. 12 Amidst rising ... Society (WDS) will jump into the popular arena of,professional tennis for the ...
    ... Back to School time again and,more schools are ... academic curriculum. According to a national survey, nearly ... to 12, are overweight or,obese. And, the 2000 ... 67,percent African American and has experienced an increase ...
    ... 1,000 eye care practices participating in nationwide effort -, ... Back to,School time, Optos and over 1,000 of its ... comprehensive eye exam that includes,the optomap(R) Retinal Exam for ... through vision, it is vital that children of all ...
    Cached Medicine News:Health News:Wellcorps International Releases Breakthrough Multi-Benefit WellCapAM(TM) Activation Complex 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 3Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 4Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 5Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 6Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 2Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 3Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 4Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 5Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 6Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 7Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 8Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 9Health News:Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U.S. Open 2Health News:Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U.S. Open 3Health News:Video: Ochsner Medical Center 'Drives' Mobile P.E. Class to New Orleans Schools in Fight Against Child Obesity 2Health News:Optos Encourages Parents to Get Back to School Eye Exams for Their Children 2
    ... and Maximum ACT introducers represent the ... hemostasis introducers in the world. They ... introducers for use in interventional cardiology ... stenting, atherectomy, temporary pacing, endomyocardial biopsies, ...
    The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
    ... Fast-Cath, Maximum, Maximum Xtra, and Maximum ... of standard and specialty hemostasis introducers ... as the premier hemostasis introducers for ... procedures including angiography, angioplasty, stenting, atherectomy, ...
    Rapid Exchange Stent Delivery System with Hepacoat...
    Medicine Products: